The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman

Fertil Steril. 1995 Nov;64(5):969-71. doi: 10.1016/s0015-0282(16)57911-4.

Abstract

Objective: To determine the role of opioidergic and dopaminergic activity in the suppression of GnRH0LH in a hyperprolactinemic state.

Design: Case report.

Setting: University hospital.

Patient: A 68-year-old woman with a macroprolactinoma.

Interventions: Serial 10-hour IV infusions of naloxone and metoclopramide.

Main outcome measure: Serum LH concentration.

Results: Naloxone induced a small but significant rise of serum LH levels, which displayed a pulsatile pattern. By contrast, metoclopramide elicited no significant response in LH secretion.

Conclusion: Opioidergic but not dopaminergic neurotransmission plays a direct role in the suppression of LH secondary to hyperprolactinemia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bromocriptine / pharmacology
  • Dopamine Agonists / pharmacology
  • Dopamine Antagonists / administration & dosage
  • Dopamine Antagonists / pharmacology*
  • Female
  • Follicle Stimulating Hormone / blood
  • Humans
  • Hyperprolactinemia / blood*
  • Hypogonadism / blood*
  • Injections, Intravenous
  • Luteinizing Hormone / blood*
  • Metoclopramide / administration & dosage
  • Metoclopramide / pharmacology*
  • Naloxone / administration & dosage
  • Naloxone / pharmacology*
  • Narcotic Antagonists / administration & dosage
  • Narcotic Antagonists / pharmacology*
  • Pituitary Neoplasms / blood
  • Postmenopause / blood*
  • Prolactin / blood
  • Prolactinoma / blood

Substances

  • Dopamine Agonists
  • Dopamine Antagonists
  • Narcotic Antagonists
  • Naloxone
  • Bromocriptine
  • Prolactin
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Metoclopramide